1gkc: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:1gkc.gif|left|200px]]<br /><applet load="1gkc" size="350" color="white" frame="true" align="right" spinBox="true"
[[Image:1gkc.gif|left|200px]]
caption="1gkc, resolution 2.30&Aring;" />
 
'''MMP9-INHIBITOR COMPLEX'''<br />
{{Structure
|PDB= 1gkc |SIZE=350|CAPTION= <scene name='initialview01'>1gkc</scene>, resolution 2.30&Aring;
|SITE= <scene name='pdbsite=BUA:Zn+Binding+Site+For+Chain+B'>BUA</scene>
|LIGAND= <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene> and <scene name='pdbligand=BUM:2-AMINO-N,3,3-TRIMETHYLBUTANAMIDE'>BUM</scene>
|ACTIVITY= [http://en.wikipedia.org/wiki/Gelatinase_B Gelatinase B], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.35 3.4.24.35]
|GENE=
}}
 
'''MMP9-INHIBITOR COMPLEX'''
 


==Overview==
==Overview==
Line 7: Line 16:


==About this Structure==
==About this Structure==
1GKC is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=CA:'>CA</scene>, <scene name='pdbligand=ZN:'>ZN</scene> and <scene name='pdbligand=BUM:'>BUM</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Gelatinase_B Gelatinase B], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.35 3.4.24.35] Known structural/functional Site: <scene name='pdbsite=BUA:Zn+Binding+Site+For+Chain+B'>BUA</scene>. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1GKC OCA].  
1GKC is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1GKC OCA].  


==Reference==
==Reference==
Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor., Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA, J Mol Biol. 2002 May 24;319(1):173-81. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=12051944 12051944]
Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor., Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA, J Mol Biol. 2002 May 24;319(1):173-81. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12051944 12051944]
[[Category: Gelatinase B]]
[[Category: Gelatinase B]]
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
Line 23: Line 32:
[[Category: matrix metalloprotease]]
[[Category: matrix metalloprotease]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:51:06 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 11:24:16 2008''

Revision as of 12:24, 20 March 2008

File:1gkc.gif


PDB ID 1gkc

Drag the structure with the mouse to rotate
, resolution 2.30Å
Sites:
Ligands: , and
Activity: Gelatinase B, with EC number 3.4.24.35
Coordinates: save as pdb, mmCIF, xml



MMP9-INHIBITOR COMPLEX


OverviewOverview

Matrix metalloproteinases (MMPs) and their inhibitors are important in connective tissue re-modelling in diseases of the cardiovascular system, such as atherosclerosis. Various members of the MMP family have been shown to be expressed in atherosclerotic lesions, but MMP9 is consistently seen in inflammatory atherosclerotic lesions. MMP9 over-expression is implicated in the vascular re-modelling events preceding plaque rupture (the most common cause of acute myocardial infarction). Reduced MMP9 activity, either by genetic manipulation or through pharmacological intervention, has an impact on ventricular re-modelling following infarction. MMP9 activity may therefore represent a key mechanism in the pathogenesis of heart failure. We have determined the crystal structure, at 2.3 A resolution, of the catalytic domain of human MMP9 bound to a peptidic reverse hydroxamate inhibitor as well as the complex of the same inhibitor bound to an active-site mutant (E402Q) at 2.1 A resolution. MMP9 adopts the typical MMP fold. The catalytic centre is composed of the active-site zinc ion, co-ordinated by three histidine residues (401, 405 and 411) and the essential glutamic acid residue (402). The main differences between the catalytic domains of various MMPs occur in the S1' subsite or selectivity pocket. The S1' specificity site in MMP9 is perhaps best described as a tunnel leading toward solvent, as in MMP2 and MMP13, as opposed to the smaller pocket found in fibroblast collagenase and matrilysin. The present structure enables us to aid the design of potent and specific inhibitors for this important cardiovascular disease target.

About this StructureAbout this Structure

1GKC is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor., Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM, Barratt DG, Slater AM, McPheat WL, Waterson D, Henney AM, Pauptit RA, J Mol Biol. 2002 May 24;319(1):173-81. PMID:12051944

Page seeded by OCA on Thu Mar 20 11:24:16 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA